Soligenix boosts ATM stock capacity by $2.96M
Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an existing At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,956,000.
Rhea-AI Filing Summary
Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an existing At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,956,000.
The company previously sold approximately $3,445,000 of common stock under this agreement pursuant to an earlier prospectus supplement. A legal opinion from Duane Morris LLP covering the additional $2,956,000 of common stock is included as an exhibit, along with the related consent and an Inline XBRL cover page data file.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Additional ATM capacity: $2,956,000
Prior ATM sales: $3,445,000
2 metrics
Additional ATM capacity
$2,956,000
Increase in maximum aggregate offering amount of common stock
Prior ATM sales
$3,445,000
Common stock sold previously under the Sales Agreement
Key Terms
prospectus supplement, At Market Issuance Sales Agreement, legal opinion, Inline XBRL
4 terms
prospectus supplement regulatory
"filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
At Market Issuance Sales Agreement financial
"issuable under the At Market Issuance Sales Agreement dated January 23, 2026"
An at market issuance sales agreement is a setup where a company arranges for an agent to sell newly issued shares directly into the public market at the current trading price, usually over time as needed. It matters to investors because it gives the company quick, flexible access to cash without setting a fixed price, but can dilute existing shareholders and affect the stock’s supply and short‑term price behavior—like a shop owner adding extra items to a shelf and selling them at whatever the going price is.
legal opinion regulatory
"A copy of the legal opinion as to the legality of the $2,956,000 of shares of common stock"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What did Soligenix (SNGX) change in its at-the-market offering?
Soligenix increased the maximum aggregate offering amount of common stock issuable under its At Market Issuance Sales Agreement by $2,956,000. This expands the capacity of its existing at-the-market program documented in a new prospectus supplement.
How much stock has Soligenix (SNGX) already sold under the Sales Agreement?
Soligenix previously sold approximately $3,445,000 of common stock under the At Market Issuance Sales Agreement. Those sales were made pursuant to an earlier prospectus supplement before the current $2,956,000 increase.
Who is Soligenix’s sales agent for the at-the-market offering?
Rodman & Renshaw LLC acts as sales agent under Soligenix’s At Market Issuance Sales Agreement dated January 23, 2026. The newly filed prospectus supplement continues to use this agreement for additional common stock issuances.
What legal opinions support Soligenix’s updated offering capacity?
A legal opinion from Duane Morris LLP covers the legality of the additional $2,956,000 of Soligenix common stock under the Sales Agreement. Duane Morris LLP also provided a related consent filed as a separate exhibit.
Which SEC form did Soligenix (SNGX) use for this disclosure?
Soligenix used a Form 8-K to disclose the filing of its new prospectus supplement. The 8-K describes the increased $2,956,000 capacity and lists the Duane Morris LLP legal opinion and consent as exhibits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
